IGFALS (Gene)

Organism:

Homo sapiens

Synonyms:ACLSD, ALS, ENTREZ:3483, HGNC:5468, IGFALS, MIM:601489, NM_001146006, NM_004970, NP_001139478, NP_004961, NR_027389, insulin like growth factor binding protein acid labile subunit

Omim:OMIM:601489

Id:ENSG00000099769

Hgnc:HGNC:5468

Entrez:3483

Ensembl:ENSG00000099769

Description:insulin like growth factor binding protein acid labile subunit

The protein encoded by this gene is a serum protein that binds insulin-like growth factors, increasing their half-life and their vascular localization. Production of the encoded protein, which contains twenty leucine-rich repeats, is stimulated by growth hormone. Defects in this gene are a cause of acid-labile subunit deficiency, which maifests itself in a delayed and slow puberty. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Mar 2009]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View IGFALS's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with IGFALS.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using IGFALS.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for IGFALS.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with IGFALS.

Results found

Linked to

	Label	Description
	GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE241036 0 V 1 ETHANOL MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE82110,GSE82299 1 V 0 ACRIFLAVINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE236228 penfluridol 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE220520 3 V 4 ETHANOL MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE164521 0 V 1 NITRIC OXIDE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE241036 0 V 3 ETHANOL MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE185519 3 V 5 GILTERITINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 7 V 2 CRIZOTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE241036 0 V 1 ETHANOL MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE82110,GSE82299 1 V 0 ACRIFLAVINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 saha 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE236228 penfluridol 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE220520 3 V 4 ETHANOL MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE164521 0 V 1 NITRIC OXIDE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE241036 0 V 3 ETHANOL MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE185519 3 V 5 GILTERITINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 7 V 2 CRIZOTINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.